Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylene blue plus vitamin C and N-acetylcysteine for critically ill COVID-19 patients
IRCT20191228045924N1Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of methylene blue, ascorbic acid and acetylcysteine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Respiratory rate, Oxygen saturation and 2 more. Started Apr 2020; status: completed.
02
Drugs
methylene blueascorbic acidacetylcysteine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20191228045924N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191228045924N1.